Medexus Pharmaceuticals (TSX:MDP) Total Stockholders Equity: C$67.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDP Medexus Pharmaceuticals Inc TSX:MDP
52 GF Score
Price C$5.02
GF Value C$1.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Total Stockholders Equity?

Medexus Pharmaceuticals TSX:MDP +2.87% 52 Total Stockholders Equity is C$67.2 Mil as of Mar. 2026. GuruFocus rates TSX:MDP with a GF Score™ of 52/100 and a GF Value™ of C$1.87 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Medexus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was C$67.2 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Medexus Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was C$2.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Medexus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.45.

Medexus Pharmaceuticals  (TSX:MDP) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Medexus Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(67.214-0)/32.026
=2.10

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Medexus Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(3.036 + 27.51) / 67.214
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Total Stockholders Equity Related Terms

Medexus Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Total Stockholders Equity Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.53 30.72 41.05 74.86 67.21

Medexus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.86 72.39 72.52 72.03 67.21
TSX:MDP
52GF Score
Medexus Pharmaceuticals Inc TSX:MDP
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of C$67.2 Mil mean?
Medexus Pharmaceuticals (TSX:MDP) has a Total Stockholders Equity of C$67.2 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Total Stockholders Equity too high?
Medexus Pharmaceuticals' current Total Stockholders Equity is C$67.2 Mil. Overall, Medexus Pharmaceuticals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Total Stockholders Equity compare to ZTS?
Medexus Pharmaceuticals' Total Stockholders Equity of C$67.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Total Stockholders Equity is C$67.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.87, compared to a current price of C$5.02 — trading 168.4% above its estimated fair value. The current Total Stockholders Equity is C$67.2 Mil. Medexus Pharmaceuticals' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Total Stockholders Equity is C$67.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of C$5.02 is trading 168.4% above its estimated GF Value™ of C$1.87. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSX:MDP:

  • Total Stockholders Equity: C$67.2 Mil
  • GF Value™: C$1.87 vs. price of C$5.02 (168.4% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAP731:Germany
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
52GF Score

Get the complete analysis for TSX:MDP

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.02
Price
C$1.87
GF Value